# Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes

> **NCT05653518** · NA · RECRUITING · sponsor: **University of Virginia** · enrollment: 40 (estimated)

## Conditions studied

- Type 1 Diabetes

## Interventions

- **DEVICE:** Tandem t:slim X2 with Control-IQ Technology
- **DEVICE:** Sensor augmented pump (SAP) therapy

## Key facts

- **NCT ID:** NCT05653518
- **Lead sponsor:** University of Virginia
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-09
- **Primary completion:** 2027-03-30
- **Final completion:** 2027-03-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05653518

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05653518, "Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05653518. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*